Evidence & Research Status
Clinical outcomes and biomarker results are not the same kind of evidence, even though headlines often treat them interchangeably. A biomarker can improve dramatically in a trial while the clinical…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
Clinical outcomes and biomarker results are not the same kind of evidence, even though headlines often treat them interchangeably. A biomarker can improve dramatically in a trial while the clinical outcomes that actually matter to patients — fewer heart attacks, longer survival, better function — fail to budge. That’s exactly what happened in Novo Nordisk’s Phase 3 ZEUS trial, and it’s a pattern worth understanding well beyond this one drug, because it shows up constantly in longevity, inflammation, and metabolic research.
What ZEUS Actually Tested
Ziltivekimab is a monoclonal antibody designed to block interleukin-6 (IL-6), an inflammatory signaling pathway linked to cardiovascular risk. ZEUS enrolled more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation (hsCRP ≥2 mg/L), and tested whether monthly ziltivekimab could reduce major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal heart attack, or non-fatal stroke — compared with placebo.
On July 31, 2026, Novo Nordisk reported that ziltivekimab did exactly what it was designed to do at the biological level: it engaged the IL-6 pathway and produced the expected reductions in free IL-6 and hsCRP. But that biomarker improvement did not translate into fewer cardiovascular events — the hazard ratio for MACE was 0.99 (95% CI, 0.88–1.11), meaning no statistically meaningful reduction in risk. Patients on ziltivekimab also experienced more serious infections than those on placebo, a safety signal consistent with suppressing an immune-signaling pathway.
The Difference Between a Mechanism, a Biomarker, and an Outcome
ZEUS is a clean illustration of three distinct levels of evidence that get collapsed into one “it works” headline more often than they should:
| Evidence Level | What It Shows | ZEUS Result |
|---|---|---|
| Mechanism | The compound engages its intended biological target | Confirmed — IL-6 pathway inhibited |
| Biomarker | A measurable lab value changes in the expected direction | Confirmed — hsCRP and free IL-6 dropped |
| Clinical outcome | Patients experience fewer events, better function, or longer survival | Not met — no MACE reduction (HR 0.99) |
A compound can clear the first two levels and still fail the third. That’s why regulators and serious researchers weight outcome trials so heavily over mechanism or biomarker data alone — and why “reduces inflammation” or “improves a biomarker” is a meaningfully weaker claim than “reduces cardiovascular events.”
Why Promising Biology Still Fails in Phase 3
ZEUS-style outcomes happen for several overlapping reasons: the biomarker being targeted may not be the true causal driver of the disease, the effect size may be real but too small to matter clinically, the studied population may not be the one that benefits most, competing biological pathways may compensate, or the safety tradeoffs (like the increased infection rate seen here) may offset any modest benefit. None of these possibilities mean the underlying biological theory was worthless — inflammation remains a legitimate area of cardiovascular research. It means this specific drug, dose, and population did not clear the bar this trial set.
Why This Matters Beyond Ziltivekimab
The same three-level structure applies directly to peptide and longevity research: an epigenetic-clock shift, a lean-mass measurement, or a mitochondrial marker are all biomarker-level findings, not proof of a clinical outcome like reduced mortality or preserved function. Framing a biomarker result as if it were an established health outcome is one of the most common ways clinical research gets overstated in consumer-facing content — and it’s avoidable simply by naming which level a given finding actually sits at.
A Quick Checklist Before Trusting a Result
Before treating any research claim as settled, it helps to ask four questions: Was the biological mechanism actually confirmed, or assumed? Did a relevant biomarker move in the expected direction, and by how much? Was an adequately powered, controlled trial run to test a real clinical outcome — not just the biomarker? And if an outcome trial was run, did it actually meet its primary endpoint, or did the drug simply avoid making things worse? Applying that checklist consistently is a better predictor of whether a compound will hold up in later research than any single early result, no matter how encouraging the biomarker movement looks.
Open Questions for Researchers
Two related Novo Nordisk cardiovascular outcomes trials for ziltivekimab — HERMES (heart failure) and ARTEMIS (post-heart-attack populations) — are still running and expected to read out in the first half of 2027; it remains to be seen whether a different patient population or endpoint produces a different result for the same mechanism. It’s also worth asking, for any compound marketed on a biomarker claim: has an adequately powered outcome trial actually been run, or is the marketing resting on mechanism and biomarker data alone?
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.